MedTrace Logo

A Trial of PDL192 in Subjects With Advanced Solid Tumors

NCT00738764 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-01-06

No results posted yet for this study

Summary

This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

PDL192

Humanized anti-TWEAK receptor monoclonal IgG1 antibody

Sponsors & Collaborators

Principal Investigators

  • Mihail Obrocea, MD · Abbott Biotherapeutics Corp.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738764 on ClinicalTrials.gov